Ngaba ubungqina obukhoyo buxhasa ukusetyenziswa kwayo?
Ngaba kunokwenzeka ukuba iziyobisi ezisetyenziselwa ukunyanga i-opioid kunye noxilongo lwezobisi zingaphucula ubomi kunye nembono yabantu abaphila nge- multiple sclerosis (MS) ?
Olunye uphando lubonisa ukuba lungenzeka. Nangona ingavunyelwanga ukusetyenziswa okunjalo, i-do-ne-naltrexone ephantsi (i-LDN) iyanqunyulwa ngokunyuka-ilebula ukuphatha ukukhathala okuhlobene ne-MS , uphawu oluqhelekileyo nolusoloko lukhubaza lwesifo.
Ukusetyenziswa kweNaltrexone
I-Naltrexone yavunywa yi-US Food Administration and Drug Administration ngo-1984 ukwenzela unyango lwe-opioid umlutha kwaye ngo-1994 ukunyangwa kwe-alcohol use disorder (AUD). Kwi-dose epheleleyo ephakanyisiweyo (50 ukuya ku-100 milligram ngosuku), i-naltrexone ibimbela umphumo we-opioids kwaye inciphisa umnqweno womntu wokusela.
Kuzo zombini amandla, i-naltrexone iye yaboniswa ukuba ihlalutye kwiziphumo ezimbi ekuphiliseni ukongezelela kodwa ingenokuba yinzuzo xa isetyenziswe njengenxalenye yenkqubo yokwenza unyango ngqo.
Ukukhishwa kweTayiti yokusetyenziswa kweNaltrexone
Ngelo xesha i-naltrexone yaqala ukuphuhliswa, abaphandi kwiKholeji yaseMatriki yasePennsylvania baqala ukufundisisa ukusetyenziswa kwayo ekuphatheni izifo ezizimelayo (apho i-immune system ihlasela ngamangqamuzana omzimba).
I-Multiple sclerosis ikholelwa ngabantu abaninzi ukuba ibangelwe impendulo yokuzimela kwaye yayiphakathi kwabaviwa bokuqala uphando. Oko abaphandi bafumene kukuba ukunyuka kwezilwanyana eziphantsi kakhulu kwakusungula ukuveliswa kwe-hormone endorphin, okubangelwa kumanqanaba okwandisa amandla kunye nempendulo enamandla yokuchasa.
Kuyafana nento eyenzeka ngexesha lokukhulelwa apho ukuveliswa kwemveliso ye-endorphin ehambelana nexesha elide lokuxolelwa kwe-MS.
Nangona kungabikho nawuphi na ubungqina obunzima beklinikhi ukuxhasa i-hypothesis, abanye abaphandi bakholelwa ukuba i-LDN inokukwazi ukunciphisa ubunzima kunye neempawu ze-MS ezinjengokukhathala, intlungu, ukunyaniseka , ukungasebenzi , kunye nokudandatheka .
Iingcebiso Zonyango
Xa kunqunywe kwizilwanyana ezincinci (ngaphantsi kweepesenti ezili-10 zezinto ezisetyenziselwa unyango lweziyobisi), i-LDN ithathwa njengekhuselekile kwaye ibekezeleke kakuhle.
Iidayari eziqhelekileyo ezichazwe kubantu abane-MS ukusuka kwi-1.5 milligram ukuya kwi-4.5 milligrams ngosuku. Kucetyiswa ukuba abantu abanaluphi uhlobo lokungcolisekanga bangathathi ngaphezu kwee-milligrams zemihla ngemihla njengoko kunokufaka isandla ekumanyaniseni ukuqina.
I-LD ingathathwa kunye okanye ngaphandle kokutya kodwa imele ithathwe phakathi kwe-9: 00 ntambama kunye nobusuku bobusuku ukuze ihambisane nomsebenzi wenkululeko yemvelo ye-endorphin.
Impembelelo echaphazelekayo yecala ye-LDD iiphupha ezicacileyo ezithatha ukunciphisa emva kweveki yokuqala okanye ezimbini. Ngokuqhelekanga, ukucasula kuye kwaziwa ukuba kwenzeka.
Ukuqwalaselwa kunye nokuchasene
Enye yeengxabano eziphambili ekusebenziseni i-LDN ukusebenzisana kwayo kunye nezidakamizwa ezininzi eziguqulwa zizifo ezisetyenziselwa ukuphatha i-MS. Ngokusekelwe kwisenzo se-pharmacokinetic zamachiza, i-LDN ayifanele isetyenziswe nge- Avonex , Rebif , okanye i- Betaseron . Ngokwahlukileyo, kubonakala kungekho nto ingqubana neCopaxone .
Ngenxa yokuba ikhutshwe emzimbeni ngenxa yesibindi, i-LDN ayikhuthazwa kubantu abane-hepatitis, isifo sesibindi, okanye i-cirrhosis.
I-LDN akufuneki idibaniswe nayo nayiphina imithi esekelwe kwi-opiate equka i-oxycontin (oxycodone), i-Vicodin (i-hydrocodone) .kunjalo ne-codein-based based syrups.
Ukuphonononga Ubungqina Boku
Nangona uvumelwane oludumileyo lunokubonisa ukuba i-LDN inegalelo ekuphuculeni impilo kunye nenhlalakahle yabantu abane-MS, ubungqina boqobo buxutywe kakhulu. Phakathi kwabo:
- Uphononongo olwenziwa eYunivesithi yaseCalifornia eSan Francisco lwabandakanya abantu abangama-80 abane-MS abaye baphathwa nge-LDN ngaphezu kweeveki ezisibhozo. Ngelixa i-LDN ayinakuguqula umsebenzi okanye umthamo wabathathi-nxaxheba, yanikezela ukuphucula okubalulekileyo kwimilinganiselo yabo yobomi (kuquka ukunciphisa intlungu nokudakumba kunye nokunyuka komsebenzi wokuqonda).
- Uvavanyo lweSigaba II oluqhutyelwe e-Italy ngo-2008 lukhangele abantu abangama-40 abane-Primary MS-progress on treatment LDN kwiinyanga ezintandathu. Ekugqibeleni, kwakukho ukuphuculwa kwamatriki kwi-spasticity (iipesenti ezingama-47 ziphuculwe, iipesenti ezili-11 zibi kakhulu) kodwa akukho phuculo kwimeko yokudakumba (ama-56 ekhulwini aphuculwe, ama-33 ekhulisa kakhulu) okanye ukukhathala (iipesenti ezingama-33 ziphuculwe, iipesenti ezingama-41 zibi kakhulu). Ngokwahlukileyo, i-LDN yadibaniswa kunye nenani elibi kakhulu leentlungu (iipesenti ezingama-28 ziphuculwe, ama-56 ekhulwini awonakele).
- Uvavanyo lweeveki ezili-17, olulawulwayo olulawulwayo ngo-2010 alufumanekanga umahluko phakathi kwabantu abathatha i-LDN okanye indawo ye-placebo okanye nayiphi na intuthuko kwimigangatho yezinto eziphilayo, kuquka nentlungu, amandla, umsebenzi wokuqonda kunye nentlalo-mpilo.
> Imithombo
> I-Cree, B .; Kornyeyeva, E .; kunye noGoodin, D. "Uvavanyo lwesilingo se-dose naltrexone ephantsi kunye nobomi bokuphila kwi-multiple sclerosis." Annals Neurol . 2010; 68 (2): 145-150.
> Gironi, M .; UMartellielli-Boneschi, F .; Sacerdote, P. et al. "Ulingo lwezilingo lwe-do-ne-naltrexone ephantsi kwi-sclerosis." Mult Scler . 2008; 14 (8): 1076-83.
> Sharaaddinzadeh, N; Moghtederi, A .; Kashipazha, D. et al. "Umphumo we-dose-naltrexone ephantsi-mgangatho wobomi bezigulane ezine-multiple sclerosis: ityala elilawulwa yindawo ehleliweyo." Mult Scler. 2010; 16 (8): 964-9.